CPT‐11 plus cisplatin in patients with advanced, untreated gastric or gastroesophageal junction carcinoma

This Phase II study assessed the response rate and toxicity profile of the combination CPT‐11 and cisplatin administered weekly to patients with untreated, advanced adenocarcinoma of the stomach or the gastroesophageal junction.

[1]  G. Schwartz,et al.  Phase II trial of weekly irinotecan plus cisplatin in advanced esophageal cancer. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  N. Kemeny,et al.  Phase I clinical and pharmacologic study of weekly cisplatin combined with weekly irinotecan in patients with advanced solid tumors. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  M. Oka,et al.  Phase I-II study of irinotecan hydrochloride combined with cisplatin in patients with advanced gastric cancer. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  U. Haglund,et al.  Initial or delayed chemotherapy with best supportive care in advanced gastric cancer. , 1994, Annals of oncology : official journal of the European Society for Medical Oncology.

[5]  A. Petroianu,et al.  Modified therapy with 5‐fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer , 1993, Cancer.

[6]  R. Simon,et al.  Optimal two-stage designs for phase II clinical trials. , 1989, Controlled clinical trials.

[7]  T. Fleming,et al.  A comparison of three chemotherapeutic regimens in the treatment of advanced pancreatic and gastric carcinoma. Fluorouracil vs fluorouracil and doxorubicin vs fluorouracil, doxorubicin, and mitomycin. , 1985, JAMA.

[8]  A. Jemal,et al.  Global cancer statistics , 2011, CA: a cancer journal for clinicians.

[9]  I. Hyodo,et al.  Phase II study of a combination of irinotecan and cisplatin against metastatic gastric cancer. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  Susan Rea Welch,et al.  Comprehensive criteria for assessing therapy-induced toxicity. , 1990, Cancer investigation.